Vivoryon Therapeutics: Funding, Investors & Team (Sep 2026)
Vivoryon Therapeutics, a biopharmaceutical company headquartered in Germany, is dedicated to conducting research and development as well as preclinical and clinical trials. Their primary focus is on creating therapeutic treatments for Alzheimer's disease and cancer, with pipeline products such as PQ912, PQ1565, and other PQ-family medications.
Vivoryon Therapeutics has raised $23.1M across 2 funding rounds on record, the most recent an undisclosed round of $6.0M announced in Oct 2025.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Vivoryon Therapeutics Company Profile and Key Stats
Latest funding round on record: Oct 2025.
Vivoryon Therapeutics Funding Rounds
Vivoryon Therapeutics raised $17.1M in an undisclosed round announced in Apr 2025.
6 months later, an undisclosed round of $6.0M was announced in Oct 2025.
Vivoryon Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Vivoryon Therapeutics Funding Compared to Other Biotechnology Startups
Vivoryon Therapeutics' latest round of $6.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Vivoryon Therapeutics in Biotechnology and Halle An Der Saale
Companies Similar to Vivoryon Therapeutics
Computomics applies AI to bioinformatics data to enable rapid understanding of genomics and drive advanced…
smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug…
Pacifico Biolabs offers fermentation biotechnology for development, production and distribution of…
NanoStruct is a biotechnology company that develops nanostructured sensor chips to identify bacteria and…
Tacalyx, a company originating from Max-Planck-Institute of Colloids and Interfaces in Potsdam, Germany, is…
Primogene is a biotechnology company that provides ingredient development, bioprocess manufacturing, and…
Mbiomics is a company in the field of biotechnology.
At EVANIUM, we make plant compounds like polyphenols and flavonoids more effective by improving their…
Picea Biosolutions is a biotechnology firm. Based on their core platform technology, they develop tailored…
KUPANDO is a pioneering biopharmaceutical firm that is developing TLR 4/7 agonists to boost innate immunity.…
Vivoryon Therapeutics Funding FAQs
What does Vivoryon Therapeutics do?
Vivoryon Therapeutics, a biopharmaceutical company headquartered in Germany, is dedicated to conducting research and development as well as preclinical and clinical trials. Their primary focus is on creating therapeutic treatments for Alzheimer's disease and cancer, with pipeline products such as PQ912, PQ1565, and other PQ-family medications.
How much funding has Vivoryon Therapeutics raised?
Vivoryon Therapeutics has raised $23.1M across 2 rounds on record. The most recent is an undisclosed round of $6.0M announced in Oct 2025.
When did Vivoryon Therapeutics last raise funding?
Vivoryon Therapeutics' most recent funding round on record is an undisclosed round of $6.0M, announced in Oct 2025.
Who founded Vivoryon Therapeutics?
FundedIQ lists Konrad Glund (Founder) at Vivoryon Therapeutics.
Where is Vivoryon Therapeutics headquartered?
Vivoryon Therapeutics is based in Halle An Der Saale, Sachsen-Anhalt, Germany.
How many employees does Vivoryon Therapeutics have?
Vivoryon Therapeutics is in the 101-250 employee band.
How does Vivoryon Therapeutics' funding compare to other Biotechnology startups?
Vivoryon Therapeutics' latest round of $6.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Vivoryon Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Vivoryon Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.